Who They Are Now
An "answers company" for questions women were told not to ask
Ask a hundred people what lives in their gut and a few will say "bacteria, probiotics, sourdough." Ask the same hundred what lives in the vaginal microbiome and the room goes quiet. Evvy exists in that silence - and has spent since 2021 filling it with measurements.
Today Evvy is a precision women's health company with about 61 employees, a New York headquarters, and one of the largest privately built datasets on female biomarkers. Its platform pairs a CLIA-certified at-home test with clinician-reviewed results, prescription treatment, and one-on-one coaching. More than 100,000 people have used it. The product is not a wellness gimmick; it is a diagnostic backed by metagenomic sequencing and, increasingly, by peer-reviewed outcomes.
"We're an answers company."
- Laine Bruzek, Co-Founder & CMO
That framing is the whole strategy. Evvy is not selling reassurance. It is selling the thing women's health has historically lacked: a number, a name for the bacteria, and a plan that follows from both.
The Problem They Saw
Medicine measured almost everything except this
Here is the inconvenient fact Evvy was built on: the vaginal microbiome - a system tied to fertility, pregnancy, STI risk, and chronic infection - was one of the least-researched ecosystems in the human body. Bacterial vaginosis, the most common vaginal condition worldwide, recurs in more than half of patients after standard treatment. The standard treatment had barely changed in decades.
Conventional testing looked for a short list of usual suspects and called it a day. If your symptoms did not fit the list, you were sent home, sometimes repeatedly. The gap was not biological. It was a data gap - nobody had bothered to collect the high-resolution picture.
The vaginal microbiome was a black box. Evvy decided to turn the lights on and write down what it found.
- The thesis, in plain terms
Above: the unglamorous reason a femtech startup raised $19M. Not a new drug - a new measurement.
The Founders' Bet
Two Stanford classmates, one uncomfortable hypothesis
Priyanka Jain and Laine Bruzek met at Stanford and reconvened around a hypothesis most investors would rather not discuss over lunch: that you could build a serious data company around the vaginal microbiome, and that the discomfort was exactly why the opportunity existed.
Priyanka Jain
Co-Founder & CEO
Stanford B.S. and former Head of Product at pymetrics, where she built algorithms to make hiring fairer. A United Nations Foundation Girl Up spokesperson who decided the next frontier of fairness was clinical data.
Laine Bruzek
Co-Founder & CMO
A veteran of Google Creative Lab, Tribeca Film Festival, and the Stanford d.school. Her instinct: put women's health in the places it has been overlooked, and make it look like it belongs there.
Their bet had two halves. First, that consumers would pay to understand their own bodies if the answers were real. Second, that the resulting dataset - millions of microbial readings tied to symptoms and outcomes - would become the actual moat. Forbes named both founders to its 30 Under 30 list in 2022. Fast Company called the test a World Changing Idea the same year.
"Closing the gender health data gap, starting with the vaginal microbiome."
- Evvy's founding mission
The Product
From swab to sequencing to a plan that fits
The Evvy Vaginal Health Test is the front door. A user swabs at home, mails the kit, and Evvy runs metagenomic sequencing that screens for more than 700 bacteria and fungi - a far wider net than the conventional panel. Preliminary results land in one to three days. A clinician reviews them. If treatment is warranted and the user is eligible, a personalized prescription plan follows, supported by coaching and ongoing tracking.
Vaginal Health Test
CLIA-certified metagenomic test screening 700+ bacteria and fungi.
~$159 // results in 1-3 daysUTI+ Test
Advanced UTI diagnostics, including antimicrobial resistance signals.
~$248Clinical Care
Clinician-reviewed results, Rx treatment, and 1:1 coaching.
Personalized plansComplete Probiotic
3-in-1 oral support for gut, urinary, and vaginal health.
~$55
The brand deserves its own footnote. Evvy deliberately rejected the pastel-pink, fruit-as-vulva visual clichés of women's health, drawing instead on the golden-age National Geographic look and artists like Barbara Kruger. One designer called it "a radical inversion of penis envy." It reads less like a tampon ad and more like a field guide.
A diagnostics company that looks like a museum exhibit. The aesthetics are a strategy: take the subject seriously, and people will too.
The Proof
Where the argument meets the numbers
Plenty of companies promise to "revolutionize" a category. Fewer publish. In July 2025 Evvy released what it described as the largest real-world outcomes study to date on at-home vaginal healthcare, peer-reviewed in the journal Microorganisms and built on more than 1,000 patients. The headline number is the one that matters to anyone who has cycled through repeat infections.
Bacterial vaginosis recurrence: traditional care vs. Evvy
Lower is better // source: Evvy peer-reviewed study, Microorganisms, 2025
Bars scaled to the higher recurrence rate. Roughly a one-third cut in repeat infection at a mean 4.4-month follow-up.
75.5%
Reported symptom relief at 4 weeks
78%
High adherence to treatment plans
1,000+
Patients in the published study
700+
Microbes screened per test
78% adherence is the quiet headline. Diagnostics fail when patients stop following the plan - coaching is why they didn't.
- Reading between the data points
Investors read the same tea leaves. Evvy has raised roughly $19M total, including a $14M Series A, with the Labcorp Venture Fund among its backers - useful proximity for a company whose whole value proposition is lab-grade testing at home. Vogue, TechCrunch, and Inc. have all covered the brand.
The Mission
The dataset is the point
Strip away the suppositories and the slick branding and Evvy's real product is information. Every test feeds a growing map of female biomarkers, which is how a consumer company ends up publishing peer-reviewed science. The 2026 finding - that bacterial vaginosis is not one condition but several distinct microbial subtypes - is the kind of insight you only reach with scale. You cannot subtype a disease you never measured.
Precision medicine arrived for cancer and cardiology years ago. Evvy is arguing it should arrive for vaginal health too - and bringing the receipts.
- The case for a category
The mission is unglamorous and enormous at once: collect the data medicine skipped, then use it to treat conditions that affect hundreds of millions of people. The gender health gap is not a slogan here. It is a measurable deficit Evvy is trying to close one swab at a time.
Why It Matters Tomorrow
Back to the swab in the mail
Return to where this started: a swab goes in the mail. Five years ago, that envelope would have led nowhere - no panel wide enough to read it, no dataset to compare it against, no plan waiting on the other side. The silence around the vaginal microbiome was not modesty. It was a measurement that medicine never made.
Now the envelope leads somewhere. It feeds a clinician, a coach, a treatment plan, and a research database that gets sharper with every sample. As Evvy connects the vaginal microbiome to gut and urinary health, and as its BV subtypes move from paper into the actual product experience, the swab stops being a one-time answer and becomes a continuous one.
The room is no longer quiet. That is the change. Evvy did not invent the vaginal microbiome - it just refused to keep treating it as unmentionable, and started writing down what it found. The data, finally, is talking back.
Know what's up down there. It turns out the answer was always knowable. Someone just had to build the test.
- Evvy, in its own words
